# Cannabis Bioscience International Holdings, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Cannabis Bioscience International Holdings, Inc.).

## Overview

Cannabis Bioscience International Holdings, Inc. is a Colorado-based company that has repositioned itself around medical cannabis education, clinical research services, and cannabidiol product development. It operates through three main businesses: Pharmacology University for cannabis-related education and consulting, Alpha Research Institute for clinical trials and research services, and a planned CBD product line under the VitaCookies name. The company also describes an intellectual property portfolio that includes patent applications, trademarks, and medical formulations tied to cannabis and biotechnology applications. Its business model is early-stage and capital constrained, with management explicitly stating that continued operations depend on raising funding and growing revenue from these activities.

## Products & services

• Cannabis-related education, seminars, and certification courses
• Clinical trial and CRO services under Alpha Research Institute
• CBD product development and planned VitaCookies sales
• Digital publishing, marketing, and franchising for medical cannabis
• Consulting and on-site training for cannabis industry participants
• Medical cannabis research, IP, and educational materials

- **Medical cannabis education** (45%) — Courses, seminars, certification programs, and training content for physicians, industry workers, and the public.
- **Clinical research services** (35%) — Sponsor and CRO services for clinical trials, including studies that may involve cannabis and CBD products.
- **CBD products** (15%) — Planned manufacture, marketing, and sale of cannabidiol-based consumer products under VitaCookies.
- **Publishing, consulting, and franchising** (5%) — Digital publishing, marketing support, consulting, and franchise-related activities tied to medical cannabis education.

- Cannabis-related education, seminars, and certification courses
- Clinical trial and CRO services under Alpha Research Institute
- CBD product development and planned VitaCookies sales
- Digital publishing, marketing, and franchising for medical cannabis
- Consulting and on-site training for cannabis industry participants
- Medical cannabis research, IP, and educational materials

## Customers

The company sells primarily to participants in the medical cannabis ecosystem rather than to a broad consumer base. Its education business targets physicians, industry workers, and general learners who need cannabis training, certification, and regulatory context. Its research business serves sponsors and third parties that need clinical trial execution or research support in therapeutic areas, including studies involving cannabis and CBD products. The CBD business is intended to reach end consumers through VitaCookies products, while the company’s IP and educational materials support both commercial and institutional users seeking cannabis-related knowledge and product development capabilities.

- **Physicians and healthcare professionals** (primary) — Buy certification courses and seminars focused on medical cannabis, clinical use, and related legal/ethical issues.
- **Cannabis industry workers** (primary) — Purchase training and certification to support operational knowledge, compliance, and professional development.
- **Clinical research sponsors and third parties** (primary) — Engage Alpha Research Institute for clinical trial services and research execution in therapeutic areas.
- **General public and online learners** (secondary) — Buy educational materials and seminars covering cannabis history, medicinal value, and industry basics.
- **CBD consumers** (emerging) — Potential buyers of VitaCookies cannabidiol products once commercialized.

- Physicians seeking cannabis certification and medical education
- Cannabis industry workers needing training on operations and compliance
- General public learners interested in cannabis history and medicinal use
- Clinical trial sponsors and third parties needing CRO support
- Potential CBD consumers for VitaCookies products
- Organizations seeking cannabis consulting, publishing, or franchising support

## Geography

The company is headquartered in the United States and repeatedly describes its education business as serving the U.S. market, with additional activity in Latin America and worldwide through online education. Its clinical research and CBD initiatives are also framed around U.S. cannabis and hemp regulatory developments, which are central to demand and commercialization. Because the business is still small and early-stage, geography matters less through physical manufacturing footprint and more through where cannabis laws, research permissions, and online demand allow the company to sell. The company’s exposure is therefore concentrated in the United States, with incremental reach into Latin America and other markets via digital delivery.

- **United States** (80%) — Primary market for education, clinical research, and CBD commercialization.
- **Latin America** (15%) — Referenced as a market for educational systems and online outreach.
- **Rest of world** (5%) — Online education and broader international interest.

- Headquartered in the United States
- Education business serves the U.S. market and Latin America
- Online education extends reach worldwide
- Clinical research and CBD plans are tied to U.S. cannabis regulation
- Geography is driven more by legal access than by manufacturing footprint

## Strategy

Management’s strategy is to build a niche position in medical cannabis science by combining education, clinical research, and product development under one umbrella. The company emphasizes intellectual property creation, including patent applications, trademarks, and medical formulations, as a way to differentiate itself despite limited capital and manpower. It also expects future growth from regulatory change, including broader acceptance of medical cannabis research and eventual commercialization of VitaCookies CBD products. Near term, the company’s survival strategy is to raise capital, expand sales of existing services, and convert its educational and research platform into recurring revenue.

- **Commercialize VitaCookies CBD products** (short-term) — The company believes product sales could create a new revenue stream and help move it toward profitability.
- **Expand medical cannabis education and certification** (short-term) — Education is a core operating business and can be scaled through online delivery and seminars.
- **Grow clinical research and CRO services** (medium-term) — Clinical trials provide service revenue and reinforce the company’s scientific positioning.
- **Build intellectual property and regulatory credibility** (medium-term) — Patents, trademarks, and policy participation may support differentiation and market legitimacy.

- Build a scientific and educational platform around medical cannabis
- Use clinical research capability to support credibility and commercialization
- Develop and launch VitaCookies CBD products
- Monetize IP through patents, trademarks, and formulations
- Expand online education to reach broader markets at low cost
- Raise capital to fund operations and avoid business interruption

## Risks

The company is highly exposed to going-concern and financing risk because management states it needs substantial additional capital to fund operations and repay debts. Its revenue base is small and uneven, with quarterly results showing that clinical trial contract volume can drop materially from period to period, which makes earnings volatile and hard to forecast. The business also depends on cannabis and hemp regulation, so changes in federal or state policy, DEA actions, or clinical research rules can either enable or restrict demand for its services and products. As a micro-cap company with limited capital and manpower, it faces execution risk in launching VitaCookies, scaling education, and converting IP into commercial value. More generally, the cannabis industry carries legal, compliance, reputational, and commercialization risks because market access remains fragmented and product acceptance is still evolving.

- **Going concern and liquidity shortfall** [critical] — Management disclosed substantial doubt about the ability to continue as a going concern and said the company needs additional capital to fund operations and repay debts.
- **Dependence on cannabis regulation and DEA policy** [high] — Education, research, and CBD commercialization all depend on legal access to cannabis/hemp and on the pace of federal regulatory change.
- **Revenue concentration and project timing** [high] — Clinical trial revenue can change sharply based on the number and timing of contracts in a quarter.
- **Dilution from equity financing** [high] — Management indicated future funding may come from private sales of common stock or convertible securities at discounts.

- Going-concern risk due to recurring losses and negative operating cash flow
- Financing risk because operations depend on new debt or equity capital
- Revenue volatility from fluctuating clinical trial contract activity
- Regulatory risk tied to cannabis, hemp, and DEA policy changes
- Execution risk in launching VitaCookies and scaling new products
- Dilution risk if funding is raised through equity or convertible securities

## Accounting

Revenue recognition is a key judgment area because the company earns from clinical trial contracts, education services, and online materials, each of which may be recognized at different points in time depending on performance obligations. Quarterly comparability is important because clinical trial activity and online sales can fluctuate materially, as shown by the drop in quarterly revenue tied to fewer trial contracts. Share-based compensation is also significant because officers and directors are paid in stock, which conserves cash but creates non-cash operating expense under U.S. GAAP. Management also highlights estimates for accounts receivable reserves, accrued expenses, and the recoverability of deferred tax assets, all of which can materially affect reported losses in a small company with limited operating history and recurring deficits.

- **Revenue recognition** — Clinical trial contracts and education sales
- **Share-based compensation** — Operating loss and net loss
- **Debt discounts and derivative liabilities** — Net loss and comparability across periods
- **Going concern disclosures and estimates** — Balance sheet and earnings quality

- Revenue recognition across clinical trials, education, and online sales
- Quarterly volatility from contract timing and lower online demand
- Share-based compensation for officers and directors
- Estimates for receivables, accrued expenses, and tax asset valuation allowance
- Debt discount amortization and interest expense can distort net loss
- Fair value changes in derivative liabilities may affect reported results

---

*Last updated: 2026-04-28T14:25:24.474719+00:00*